Singapore markets closed

Straits Times Index
3,378.29
-15.92(-0.47%)
S&P 500
4,070.56
+10.13(+0.25%)
Dow
33,978.08
+28.68(+0.08%)
Nasdaq
11,621.71
+109.31(+0.95%)
BTC-USD
23,222.31
-105.29(-0.45%)
CMC Crypto 200
525.65
+8.64(+1.67%)

BCRX Jan 2024 22.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.6000

0.0000

(0.00%)

As of 01:24PM EST. Market open.

Loading interactive chart…

Zacks
Wall Street Analysts Predict a 48% Upside in BioCryst (BCRX): Here's What You Should Know
The mean of analysts' price targets for BioCryst (BCRX) points to a 47.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
Participating with me today are CEO, Joh Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; and chief R&D officer, Dr. New patient starts are consistent with previous quarters, discontinuations appear to have stabilized, and we are investing more to keep this momentum going.